Syngene International Ltd.'s net profit surged during the quarter ended June 30 of fiscal 2026.
The company's bottom line climbed to Rs 86.7 crore, a 15% rise in the first quarter, as compared to Rs 75.7 crore for the same period last year, according to an exchange filing on Wednesday.
Syngene Q1 FY26 Highlights (Consolidated, YoY)
Revenue up 10.7% at Rs 875 crore versus Rs 790 crore.
Ebitda up 21.6% at Rs 206 crore versus Rs 170 crore.
Margin at 23.6% versus 21.5%.
Net profit up 14.5% at Rs 86.7 crore versus Rs 75.7 crore.
'We are pleased with the growth performance in the first quarter, which is aligned with our expectations," Chief Executive Officer Peter Bains said.
Bains emphasised that the continued conversion of pilot programmes into longer-term contracts within the company's research services business was the main driver underpinning this momentum.
"We continued to strengthen and expand our scientific platform capabilities, bringing online a state-of-the-art, dedicated peptide laboratory. While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook," he said.
Shares of Syngene closed 0.70% higher at Rs 680.75 apiece on the NSE, compared to a 0.63% rise in the benchmark Nifty. The stock has fallen 10.16% in the last 12 months and 20.7% on a year-to-date basis.
Out of the 11 analysts tracking the company, seven have a 'buy' rating on the stock, one recommends 'hold' and three gave 'sell', according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 6.1%.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
